trial

Aripiprazole Treatment of Prodromal Patients

NCTId NCT00237874
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 15 (actual)
Sponsored by Yale University
Primary completion 2007-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
15 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-02
Primary completion
2007-02
Eligibility
ALL · 13 Years · 40 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Yale UniversityLead Sponsor
Bristol-MyersCollaborator

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

2 total
Hartford, United StatesNew Haven, United States

Linked catalysts

1
Aripiprazole Treatment of Prodromal Patients — primary completion2007-02

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE2,PHASE3
Primary Completion Date
2007-02
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Yale University
company
collaborator
Bristol-Myers
company
indication
Schizophrenia
indication
Psychosis
indication
Schizophrenia
indication
investigator
Scott W. Woods, MD
person